# EDGAR Filing Document

**Accession Number:** 0001587114
**File Stem:** 0000935836-25-000579
**Filing Date:** 2025-8
**Character Count:** 21172
**Document Hash:** 269537dfdc2b7a9fee11aac5dc15cc6a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000935836-25-000579.hdr.sgml**: 20250829

**ACCESSION NUMBER**: 0000935836-25-000579

**CONFORMED SUBMISSION TYPE**: N-PX

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250829

**EFFECTIVENESS DATE**: 20250829

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** EcoR1 Capital, LLC
- **CENTRAL INDEX KEY:** 0001587114

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** N-PX
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 028-16764
- **FILM NUMBER:** 251280440

**BUSINESS ADDRESS:**
- **STREET 1:** 357 TEHAMA STREET #3
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94103
- **BUSINESS PHONE:** 415-448-6534

**MAIL ADDRESS:**
- **STREET 1:** 357 TEHAMA STREET #3
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94103

## FORM N-PX
### ANNUAL REPORT OF PROXY VOTING RECORD

## N-PX: Filer Information

**Filer CIK:** 0001587114

**Date of Report:** 06/30/2025

**Are you a Registered Management Investment Company or an Institutional Manager?:** Institutional Manager

**Is this a LIVE or TEST Filing?:** LIVE

**Is this an electronic copy of an official filing submitted in paper format?:** [ ]

### Submission Contact Information
_Not provided in this filing._

### Notification Information
**Notify via Filing Website only?:** [ ]

## N-PX: Cover Page

**Name of reporting person:** EcoR1 Capital, LLC

**Address:** 357 TEHAMA STREET #3, SAN FRANCISCO, CA 94103

**Telephone number:** 415-448-6534

**Name of agent for service:** CORPORATION SERVICE COMPANY

**Agent Address:** 251 LITTLE FALLS DRIVE, WILMINGTON, DE 19808

**Reporting Period:** Report for the year ended 06/30/2025

**SEC File Number:** 028-16764

**CRD Number (if any):** —

**Other SEC File Number (if any):** —

**LEI (if any):** 254900G27UH5KKYMY240

**Report Type (check only one):**

Institutional Manager.

- [x] Institutional Manager Voting Report

- [ ] Institutional Manager Notice Report

- [ ] Institutional Manager Combination Report

Registered Management Investment Company.

- [ ] Fund Voting Report

- [ ] Fund Notice Report

**Do you wish to provide explanatory information pursuant to Special Instruction B.4?:**

- [x] No

- [ ] Yes

**Additional information:** —

## N-PX: Summary - Included Managers

**Number of Included Institutional Managers:** 0

**Included Institutional Managers:** —

## FORM N-PX PROXY VOTING RECORD

| NAME OF ISSUER                | CUSIP     | MEETING DATE   | VOTE DESCRIPTION                                                                                                                                                                                                        | VOTE CATEGORY                |   SHARES VOTED |   SHARES ON LOAN | HOW VOTED   |   SHARES VOTED FOR OR AGAINST MANAGEMENT | FOR OR AGAINST MANAGEMENT   | OTHER INFO   |
|:---|:---|:---|:---|:---|---:|---:|:---|---:|:---|:---|
| Jazz Pharmaceuticals PLC      | 47103J105 | 07/25/2024     | To indicate, on a non-binding advisory basis, the preferred frequency of the advisory vote on the compensation of Jazz Pharmaceuticals plc's named executive officers.                                                  | SECTION 14A SAY-ON-PAY VOTES |        1013952 |                0 | ONE YEAR    |                                  1013952 | FOR                         |  |
| Jazz Pharmaceuticals PLC      | 47103J105 | 07/25/2024     | To approve, on a non-binding advisory basis, the compensation of Jazz Pharmaecuticals plc's named executive officers as disclosed in the proxy statement.                                                               | SECTION 14A SAY-ON-PAY VOTES |        1013952 |                0 | FOR         |                                  1013952 | FOR                         |  |
| Nuvation Bio Inc              | 67080N101 | 09/03/2024     | To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.                                                                                       | SECTION 14A SAY-ON-PAY VOTES |       13844016 |                0 | FOR         |                                 13844016 | FOR                         |  |
| Zymeworks Inc                 | 98985Y108 | 12/10/2024     | Advisory vote on the compensati on of named executi ve offi cers.                                                                                                                                                       | SECTION 14A SAY-ON-PAY VOTES |       13437473 |                0 | FOR         |                                 13437473 | FOR                         |  |
| Prothena                      | G72800108 | 05/13/2025     | To approve, on an advisory (non-binding) basis, the compensation of the Company's named execuve officers, as disclosed in the accompanying Proxy Statement.                                                             | SECTION 14A SAY-ON-PAY VOTES |        8266342 |                0 | FOR         |                                  8266342 | FOR                         |  |
| Day One Pharmaceuticals       | 23954D109 | 06/02/2025     | To approve, on an adivsory (non-binding) basis the compensation of the Company's named executive officers.                                                                                                              | SECTION 14A SAY-ON-PAY VOTES |         862068 |                0 | FOR         |                                   862068 | FOR                         |  |
| CRISPR Therapeutics AG        | H17182108 | 06/05/2025     | Non-binding advisory vote on the compensation paid to the Company's named executive officers.                                                                                                                           | SECTION 14A SAY-ON-PAY VOTES |        1389276 |                0 | FOR         |                                  1389276 | FOR                         |  |
| Kura Oncology Inc             | 50127T109 | 06/05/2025     | To approve, on an adivsory (non-binding) basis the compensation of the Company's named executive officers.                                                                                                              | SECTION 14A SAY-ON-PAY VOTES |        4270000 |                0 | FOR         |                                  4270000 | FOR                         |  |
| Keros Therapeutics Inc        | 492327101 | 06/04/2025     | To approve, on an adivsory (non-binding) basis the compensation of the Company's named executive officers.                                                                                                              | SECTION 14A SAY-ON-PAY VOTES |         187500 |                0 | FOR         |                                   187500 | FOR                         |  |
| Voyager Therapeutics Inc      | 92915B106 | 06/05/2025     | To approve, on an adivsory (non-binding) basis the compensation of the Company's named executive officers.                                                                                                              | SECTION 14A SAY-ON-PAY VOTES |        3917546 |                0 | FOR         |                                  3917546 | FOR                         |  |
| Apellis Pharmaceuticals Inc   | 03753U106 | 06/03/2025     | To hold an advisory vote to approve the compensation paid to our named executive officers.                                                                                                                              | SECTION 14A SAY-ON-PAY VOTES |       11895808 |                0 | FOR         |                                 11895808 | FOR                         |  |
| Apellis Pharmaceuticals Inc   | 03753U106 | 06/03/2025     | To hold an advisor vote on the frequency of future advisory votes on the compensation paid t ouor named executive officers.                                                                                             | SECTION 14A SAY-ON-PAY VOTES |       11895808 |                0 | ONE YEAR    |                                 11895808 | FOR                         |  |
| Sarepta Therapeutics          | 803607100 | 06/05/2025     | Advisory vote to approve executive compensation.                                                                                                                                                                        | SECTION 14A SAY-ON-PAY VOTES |        2800000 |                0 | FOR         |                                  2800000 | FOR                         |  |
| Verve Therapeutics Inc        | 92539P101 | 06/05/2025     | To approve our directors' renumeration report for the financial year eneded December 31, 2024.                                                                                                                          | SECTION 14A SAY-ON-PAY VOTES |        1250000 |                0 | FOR         |                                  1250000 | FOR                         |  |
| Bicycle Therapeutics          | 088786108 | 06/17/2025     | To receive and approve, on an advisory basis, the Company's U.K, statutory directors' renumeration report for the financial year eneded December 31, 2024.                                                              | SECTION 14A SAY-ON-PAY VOTES |         910000 |                0 | FOR         |                                   910000 | FOR                         |  |
| Bicycle Therapeutics          | 088786108 | 06/17/2025     | To approve, on an advisory (non-binding) basis, the compensation of the Company's named execuve officers, as disclosed in the accompanying Proxy Statement.                                                             | SECTION 14A SAY-ON-PAY VOTES |         910000 |                0 | FOR         |                                   910000 | FOR                         |  |
| Tango Therapeutics Inc        | 87583X109 | 06/05/2025     | To approve, on an adivsory (non-binding) basis the compensation of the Company's named executive officers.                                                                                                              | SECTION 14A SAY-ON-PAY VOTES |       10630736 |                0 | AGAINST     |                                 10630736 | AGAINST                     |  |
| Tango Therapeutics Inc        | 87583X109 | 06/05/2025     | Non-binding advisory vote on the frequency of future non-binding, advisory votes on the compensation of our named executive officers.                                                                                   | SECTION 14A SAY-ON-PAY VOTES |       10630736 |                0 | ONE YEAR    |                                 10630736 | FOR                         |  |
| Beam Therapeutics             | 07373V105 | 06/04/2025     | To approve, on an adivsory (non-binding) basis the compensation of the Company's named executive officers.                                                                                                              | SECTION 14A SAY-ON-PAY VOTES |         526685 |                0 | FOR         |                                   526685 | FOR                         |  |
| Neurogene Inc                 | 64135M105 | 06/12/2025     | To approve, on an adivsory (non-binding) basis the compensation of the Company's named executive officers.                                                                                                              | SECTION 14A SAY-ON-PAY VOTES |        1186381 |                0 | FOR         |                                  1186381 | FOR                         |  |
| Atara Biotherapeutics Inc     | 046513107 | 06/10/2025     | To approve, on an advisory (non-binding) basis, the compensation of the Company's named execuve officers, as disclosed in the accompanying Proxy Statement.                                                             | SECTION 14A SAY-ON-PAY VOTES |         573183 |                0 | FOR         |                                   573183 | FOR                         |  |
| Atara Biotherapeutics Inc     | 046513107 | 06/10/2025     | To approve on an advisory basis, the frequency of future advisory votes on the compensation of the Company's named executive officers.                                                                                  | SECTION 14A SAY-ON-PAY VOTES |         573183 |                0 | ONE YEAR    |                                   573183 | FOR                         |  |
| Adaptimmune Therapeutics      | 00653A107 | 05/29/2025     | To approve on a non-binding advisory basis, the compensation of the Company's named executive officers for the year ended December 31, 2024.                                                                            | SECTION 14A SAY-ON-PAY VOTES |       27404070 |                0 | FOR         |                                 27404070 | FOR                         |  |
| Adaptimmune Therapeutics      | 00653A107 | 05/29/2025     | To approve our U.K,. Statutory directors' renumeration report fo the year ended December, 31, 2024.                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |       27404070 |                0 | FOR         |                                 27404070 | FOR                         |  |
| Adaptimmune Therapeutics      | 00653A107 | 05/29/2025     | To approve, on a non-binding, advisory basis, the preferred frequency of future shareholder advisory votes on the compensation of the Company's named executive officers.                                               | SECTION 14A SAY-ON-PAY VOTES |       27404070 |                0 | ONE YEAR    |                                 27404070 | FOR                         |  |
| Whitehawk Therapeutics        | 00032Q104 | 06/11/2025     | To approve on an advisory basis, the compensation of the named executive officers identified in the 2024 Summary Compensation Table.                                                                                    | SECTION 14A SAY-ON-PAY VOTES |        1091417 |                0 | FOR         |                                  1091417 | FOR                         |  |
| Tectonic Therapeutics         | 878972108 | 06/06/2025     | Advisory approval of the compensation of the Company's Named Executive Officer.                                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |         935121 |                0 | FOR         |                                   935121 | FOR                         |  |
| Tectonic Therapeutics         | 878972108 | 06/06/2025     | Advisory vote on the frequency of stockholder votes on executive compensation                                                                                                                                           | SECTION 14A SAY-ON-PAY VOTES |         935121 |                0 | ONE YEAR    |                                   935121 | FOR                         |  |
| Xencor Inc                    | 98401F105 | 06/12/2025     | To approve, on an advisory (non-binding) basis, the compensaon of the Company's named execuve officers, as disclosed in the accompanying Proxy Statement.                                                               | SECTION 14A SAY-ON-PAY VOTES |        6144767 |                0 | FOR         |                                  6144767 | FOR                         |  |
| Crinetics Pharmaceuticals Inc | 22663K107 | 06/11/2025     | To consider and vote upon, on an advisory basis, the compensation of our named execuve officers as disclosed in this proxy statement pursuant to thecompensaon disclosure rules of the Securies and Exchange Commission | SECTION 14A SAY-ON-PAY VOTES |        4288120 |                0 | FOR         |                                  4288120 | FOR                         |  |
| Avidity Biosciences           | 05370A108 | 06/10/2025     | To consider and vote upon, on an advisory basis, the compensation of our named execuve officers as disclosed in this proxy statement pursuant to thecompensaon disclosure rules of the Securies and Exchange Commission | SECTION 14A SAY-ON-PAY VOTES |        1000000 |                0 | FOR         |                                  1000000 | FOR                         |  |
| Ginkgo Bioworks Holdings      | 37611X209 | 06/12/2025     | Advisory vote to approve executive compensation.                                                                                                                                                                        | SECTION 14A SAY-ON-PAY VOTES |        1462328 |                0 | FOR         |                                  1462328 | FOR                         |  |
| Janux Therapeutics            | 47103J105 | 06/11/2025     | Approval, on an advisory basis, of the compensaon of our named executive officers.                                                                                                                                      | SECTION 14A SAY-ON-PAY VOTES |        1469818 |                0 | FOR         |                                  1469818 | FOR                         |  |
| Janux Therapeutics            | 47103J105 | 06/11/2025     | Indication, on an advisory basis, of the preferred frequency of holding future say-on-pay votes on the compensation of our named executive officers.                                                                    | SECTION 14A SAY-ON-PAY VOTES |        1469818 |                0 | ONE YEAR    |                                  1469818 | FOR                         |  |
| AnaptysBio, Inc.              | 032724106 | 06/17/2025     | To conduct a non-binding advisory vote on the compensation of our named executive officers as disclosed in the accompanying materials.                                                                                  | SECTION 14A SAY-ON-PAY VOTES |        7880094 |                0 | FOR         |                                  7880094 | FOR                         |  |
| AnaptysBio, Inc.              | 032724106 | 06/17/2025     | To approve an amendment to our 2017 Equity Incentive Plan                                                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES |        7880094 |                0 | FOR         |                                  7880094 | FOR                         |  |
| Centessa Pharmaceuticals      | 152309100 | 06/20/2025     | To receive and approve, on an advisory basis, the Company's U.K, statutory directors' renumeration report for the financial year eneded December 31, 2024.                                                              | SECTION 14A SAY-ON-PAY VOTES |         100000 |                0 | FOR         |                                   100000 | FOR                         |  |
| Centessa Pharmaceuticals      | 152309100 | 06/20/2025     | To receive and approve the Directors' Renumeration Policy.                                                                                                                                                              | SECTION 14A SAY-ON-PAY VOTES |         100000 |                0 | FOR         |                                   100000 | FOR                         |  |
| Madrigal Pharmaceuticals      | 558868105 | 06/20/2025     | Advisory vote to approve executive compensation                                                                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |          75000 |                0 | FOR         |                                    75000 | FOR                         |  |
| Madrigal Pharmaceuticals      | 558868105 | 06/20/2025     | Advisory vote to approve the frequency of future advisory votes to approve executive compensation                                                                                                                       | SECTION 14A SAY-ON-PAY VOTES |          75000 |                0 | ONE YEAR    |                                    75000 | FOR                         |  |
| Akero Therapeutics            | 00973Y108 | 06/03/2025     | To consider and act upon a non-binding, advisory vote to approve the compensation of our named executive officers.                                                                                                      | SECTION 14A SAY-ON-PAY VOTES |         140000 |                0 | FOR         |                                   140000 | FOR                         |  |

## N-PX: Signature Block

**Reporting Person:** EcoR1 Capital, LLC

**By (Signature):** Oleg Nodelman

**By (Printed Signature):** Oleg Nodelman

**By (Title):** Manager

**Date:** 08/29/2025